MWNA
GMAB icon

Marshall Wace North America’s Genmab GMAB Stock Holding History

Marshall Wace North America’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,611
Closed -$775K – 1569
2021
Q1 		$775K Sell
23,611
-105,190
-82% -$3.96M ﹤0.01% 1104
2020
Q4 		$5.24M Sell
128,801
-345,698
-73% -$12.9M 0.02% 529
2020
Q3 		$17.4M Sell
474,499
-217,119
-31% -$7.85M 0.11% 197
2020
Q2 		$23.4M Buy
691,618
+466,374
+207% +$12.7M 0.15% 148
2020
Q1 		$4.77M Buy
+225,244
New +$5.02M 0.04% 325

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Marshall Wace North America's GMAB Position: Q2 2021 in Review

Marshall Wace North America sold out of Genmab (GMAB) in Q2 2021, closing a stake of 23,611 shares — an estimated $775K sold.

Marshall Wace North America first reported a position in GMAB in Q1 2020 and held it in 5 quarters. The position peaked at $23.4M in Q2 2020. 212 funds tracked by Wall St. Rank hold GMAB as of Q2 2021.

  • Marshall Wace North America reported no remaining Genmab position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 23,611 Genmab shares in Q2 2021, an estimated $775K.
  • Marshall Wace North America first reported a position in Genmab in Q1 2020 and held it in 5 quarters.
  • Marshall Wace North America's Genmab position peaked at $23.4M in Q2 2020.
  • 212 funds tracked by Wall St. Rank held Genmab as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.